Cargando…
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamou...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/ https://www.ncbi.nlm.nih.gov/pubmed/36176413 http://dx.doi.org/10.3389/fonc.2022.843116 |
_version_ | 1784798204707995648 |
---|---|
author | Li, Xin Xia, Chunqiu Liu, Minghui Liu, Jinghao Dong, Ming Zhao, Honglin Xu, Song Wang, Dan Wei, Sen Song, Zuoqing Chen, Gang Liu, Hongyu Chen, Jun |
author_facet | Li, Xin Xia, Chunqiu Liu, Minghui Liu, Jinghao Dong, Ming Zhao, Honglin Xu, Song Wang, Dan Wei, Sen Song, Zuoqing Chen, Gang Liu, Hongyu Chen, Jun |
author_sort | Li, Xin |
collection | PubMed |
description | Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamous non-small-cell lung cancer from September to December in 2020 and received two cycles of neoadjuvant camrelizumab plus nab-paclitaxel and nedaplatin, followed by surgical resection. All three patients had a reduction in the tumor size on CT image and not delayed planned surgery. We did not observe grade 3 or 4 adverse events. Two of the three patients achieved a major pathological response (MPR), including one complete tumor regression of the primary lung tumor. Multiplex fluorescent immunohistochemistry revealed that CD8+ T cells, FoxP3+ regulatory T cells, and PD-L1 expression on immune cells in the surgical specimen were much higher than in the pretreatment biopsy sample in patients with MPR. This was not observed in the patient without MPR. Camrelizumab plus chemotherapy could potentially be a neoadjuvant regimen for resectable IIIA squamous non-small-cell lung cancer, with a high MPR proportion, and did not compromise surgical procedure. Our findings should be validated in a future randomized clinical trial. |
format | Online Article Text |
id | pubmed-9514096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95140962022-09-28 Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases Li, Xin Xia, Chunqiu Liu, Minghui Liu, Jinghao Dong, Ming Zhao, Honglin Xu, Song Wang, Dan Wei, Sen Song, Zuoqing Chen, Gang Liu, Hongyu Chen, Jun Front Oncol Oncology Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamous non-small-cell lung cancer from September to December in 2020 and received two cycles of neoadjuvant camrelizumab plus nab-paclitaxel and nedaplatin, followed by surgical resection. All three patients had a reduction in the tumor size on CT image and not delayed planned surgery. We did not observe grade 3 or 4 adverse events. Two of the three patients achieved a major pathological response (MPR), including one complete tumor regression of the primary lung tumor. Multiplex fluorescent immunohistochemistry revealed that CD8+ T cells, FoxP3+ regulatory T cells, and PD-L1 expression on immune cells in the surgical specimen were much higher than in the pretreatment biopsy sample in patients with MPR. This was not observed in the patient without MPR. Camrelizumab plus chemotherapy could potentially be a neoadjuvant regimen for resectable IIIA squamous non-small-cell lung cancer, with a high MPR proportion, and did not compromise surgical procedure. Our findings should be validated in a future randomized clinical trial. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9514096/ /pubmed/36176413 http://dx.doi.org/10.3389/fonc.2022.843116 Text en Copyright © 2022 Li, Xia, Liu, Liu, Dong, Zhao, Xu, Wang, Wei, Song, Chen, Liu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Xin Xia, Chunqiu Liu, Minghui Liu, Jinghao Dong, Ming Zhao, Honglin Xu, Song Wang, Dan Wei, Sen Song, Zuoqing Chen, Gang Liu, Hongyu Chen, Jun Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title | Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title_full | Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title_fullStr | Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title_full_unstemmed | Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title_short | Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases |
title_sort | neoadjuvant camrelizumab and chemotherapy in patients with resectable stage iiia squamous non-small-cell lung cancer: clinical experience of three cases |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/ https://www.ncbi.nlm.nih.gov/pubmed/36176413 http://dx.doi.org/10.3389/fonc.2022.843116 |
work_keys_str_mv | AT lixin neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT xiachunqiu neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT liuminghui neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT liujinghao neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT dongming neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT zhaohonglin neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT xusong neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT wangdan neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT weisen neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT songzuoqing neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT chengang neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT liuhongyu neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases AT chenjun neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases |